- Exchange: Oslo
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Algeta ASA
+ Add to WatchlistALGETA:NO
209.00 NOK 2.20 1.06%
Share
As of 10:25:23 ET on 05/24/2013.
More on ALGETA
News for Algeta ASA (ALGETA)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Algeta Surges to Record After Prostate Cancer Drug Approval
- Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug
- Norway’s OBX Index Falls to 3-Month Low as Oil Drops: Oslo Mover
- Algeta Sees ’Widespread’ Interest in Thorium Cancer Technology
- Algeta Advances Amid Prostate Cancer Drug Expansion: Oslo Mover
- Algeta Surges After Positive Alpharadin Studies: Oslo Mover
- Norway Oil Rush Turns to Fool’s Gold for Closing Towns
- Amgen’s Xgeva Wins U.K. NICE Backing for Some Cancer Patients
- Algeta Advances as Analysts Predict Commercial Push: Oslo Mover
- NORDIC DAYBOOK: Danish Central Bank Warns Against Stimulus
- NORDIC DAYBOOK: Norway’s Central Bank May Raise Rates Today
- Algeta Enters Research Collaboration to Evaluate Thorium
- Nordic Stocks: Autoliv, Boliden, Maersk, Novo Nordisk, Yara
- Advent Venture Raises $120 Million for First Life Sciences Fund
- Norway Oil Money Boosts Health as Biotechs Dig Up Cancer Cures
- Algeta ASA : Algeta ASA : Share capital increase related to exercise of employee options in Tranche 2 has been registered Published May 22, 2013
- Algeta ASA : Algeta ASA : Share capital increase related to exercise of employee options in Tranche 1 has been registered Published May 21, 2013
- Algeta ASA : Algeta ASA : Price per share sold by primary insiders Published May 16, 2013
- Algeta ASA : Algeta ASA : Option exercise (Tranche 2) and issuance of shares under option program in Algeta ASA (the "Company" Published May 16, 2013
- Algeta ASA : CORRECTION: Algeta ASA : Option exercise and issuance of shares under option program in Algeta ASA (the "Company" Published May 16, 2013
- Algeta ASA : Algeta ASA : Option exercise and issuance of shares under option program in Algeta ASA (the "Company" or "Algeta") Published May 16, 2013
- BAYER RECEIVES US FDA APPROVAL FOR XOFIGO (ENG) Published May 16, 2013
- Algeta ASA: New data and analyses from clinical trials of Xofigo(R) (radium Ra 223 dichloride) to be presented at ASCO Published May 16, 2013
- Algeta ASA : Algeta ASA : New data and analyses from clinical trials of Xofigo® (radium-223 dichloride) to be presented at Published May 16, 2013
- Bayer to Present New Data Across Oncology Portfolio at ASCO 2013 Published May 15, 2013
- Algeta Announces That Xofigo(R) (Radium Ra 223 Dichloride) Injection Has Been Approved by the US FDA as Treatment for Castration Published May 15, 2013
- Algeta ASA : Algeta announces that Xofigo® (radium-223 dichloride) has been approved by the US FDA Published May 15, 2013
- Bayer Receives U.S. FDA Approval for Xofigo® (radium Ra 223 dichloride) Injection as a New Treatment for Castration-Resistant Published May 15, 2013
- Algeta results for the first quarter 2013 Published May 15, 2013
- Algeta ASA : Changes in Algeta's Financial Calendar 2013 Published May 15, 2013
- China’s Stocks Rise After Biggest Slump in a Month
- Elan Board Unanimously Rejects $6.4 Billion Takeover Offer
- BioMarin Gains on Prospects for Experimental Cancer Drug
- Kasowitz Benson, Eversheds, Latham: Business of Law
- Actavis Lowers Tax Rate to 17% After Warner Chilcott Deal
- ‘Love Hormone’ Promises Safer Births After Pfizer Flop
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’
- Actavis to Buy Warner Chilcott in Women’s Health Effort
- Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash
- Elan Makes Two Acquisitions for $380 Million
- ThromboGenics Reports Jetrea Sales as Drug Fails Mid-Stage Study
- Eu Yan Sang Jumps Most Since Feb. 2012 on Deal: Singapore Mover
- Teva U.S. Jump Widens Holiday Discount: Israel Overnight
- Chesapeake Partners Holdings in 1st Quarter: 13F Alert
- Actavis Gaining More From Purchase Than Sale: Real M&A
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page